Kristina Beeler, PhD (Biognosys)
Genomics and transcriptomics provide only a limited understanding of disease biology, which results in a significant stumbling block to the success of precision medicine. Proteomics has emerged as the method of choice to answer some of the most challenging questions across the drug development pipeline, from novel target discovery to large-scale biomarker studies. For almost 15 years, Biognosys has been at the leading-edge of proteomics. Over this time, we have developed industry-leading solutions that have enabled some of the most innovative biopharma companies to unlock discoveries and progress their drug development pipelines.
The registration for the event is still open:
Short Bio Kristina Beeler:
Kristina leads the business activities of the services offering of Biognosys. Her team enables Biognosys’ global partners to utilize proteomics to address the key challenges in their research.